Literature DB >> 22664931

Prostate cancer: New PSA screening guideline faces widespread opposition.

Sarah Payton.   

Abstract

Entities:  

Year:  2012        PMID： 22664931     DOI： 10.1038/nrurol.2012.124

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  3 in total

1.  What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation.

Authors:  William J Catalona; Anthony V D'Amico; William F Fitzgibbons; Omofolasade Kosoko-Lasaki; Stephen W Leslie; Henry T Lynch; Judd W Moul; Marc S Rendell; Patrick C Walsh
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

2.  Prostate cancer screening: what we know, don't know, and believe.

Authors:  Otis W Brawley
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

3.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391
  3 in total
  5 in total

1.  Prostate cancer: Proponents of PSA screening boosted by new study.

Authors:  Mina Razzak
Journal:  Nat Rev Urol       Date:  2012-08-21       Impact factor: 14.432

2.  Outcome of repeated prostatic biopsy during active surveillance: implications for focal therapy.

Authors:  Ghassan A Barayan; Armen G Aprikian; James Hanley; Wassim Kassouf; Fadi Brimo; Louis R Bégin; Simon Tanguay
Journal:  World J Urol       Date:  2014-11-12       Impact factor: 4.226

Review 3.  Multigene panels in prostate cancer risk assessment: a systematic review.

Authors:  Julian Little; Brenda Wilson; Ron Carter; Kate Walker; Pasqualina Santaguida; Eva Tomiak; Joseph Beyene; Muhammad Usman Ali; Parminder Raina
Journal:  Genet Med       Date:  2015-10-01       Impact factor: 8.822

Review 4.  Management of low risk prostate cancer-active surveillance and focal therapy.

Authors:  Laurence Klotz; Mark Emberton
Journal:  Nat Rev Clin Oncol       Date:  2014-05-13       Impact factor: 66.675

5.  Depression and coronary heart disease.

Authors:  Karina W Davidson
Journal:  ISRN Cardiol       Date:  2012-11-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.